Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 37 out of 100. Down syndrome and Alzheimer's

Topic: Brain proteins, microglia and lab models

Neurofibrillary tangles (NFTs) form in a number of neurodegenerative disorders. In Alzheimer disease (AD), intracellular NFTs (iNFTs) develop along with extracellular beta-amyloid (Abeta) deposits. Reports on whether NFTs have Abeta associated with them are inconsistent. Here we study NFTs and their direct relationship with Abeta-like fragments in cases of AD, Down Syndrome, and the parkinsonism-dementia complex of Guam, using a panel of antibodies which recognize different epitopes of Abeta. In all diseases, as well as in the aged controls, the majority of extracellular NFTs (eNFTs) are stained with antibodies recognizing the 40 carboxy-terminal of Abeta, but not other epitopes. Such staining is morphologically distinguishable from the previously described Abeta positive 'tangle associated amyloid deposits' (TAADs), which surround some eNFTs, and are immunopositive for all epitopes of the Abeta molecule. Some iNFTs are immunoreactive with antibodies to the 42 carboxy-terminal epitope, and, to a lesser extent, with antibodies to midportions and more N-terminal epitopes of Abeta. These results may indicate a direct interaction between Abeta and NFTs, although secondary deposition or crossreactivity with other epitopes associated with NFTs cannot be ruled out.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Schwab, C., Akiyama, H., McGeer, E. G., & McGeer, P. L. (1998). Extracellular neurofibrillary tangles are immunopositive for the 40 carboxy-terminal sequence of beta-amyloid protein. Journal of neuropathology and experimental neurology. https://doi.org/10.1097/00005072-199812000-00004

Vancouver

Schwab C, Akiyama H, McGeer EG, McGeer PL. Extracellular neurofibrillary tangles are immunopositive for the 40 carboxy-terminal sequence of beta-amyloid protein. Journal of neuropathology and experimental neurology. 1998. doi:10.1097/00005072-199812000-00004. PMID: 9862635.

BibTeX

@article{schwab1998-9862635,
  author  = {Schwab, C. and Akiyama, H. and McGeer, E. G. and McGeer, P. L.},
  title   = {{Extracellular neurofibrillary tangles are immunopositive for the 40 carboxy-terminal sequence of beta-amyloid protein}},
  journal = {Journal of neuropathology and experimental neurology},
  year    = {1998},
  doi     = {10.1097/00005072-199812000-00004},
  pmid    = {9862635},
  url     = {https://doi.org/10.1097/00005072-199812000-00004}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This tissue study found that most extracellular neurofibrillary tangles stained with antibodies to the 40 carboxy-terminal of beta-amyloid in Alzheimer disease, Down syndrome and Guam parkinsonism-dementia complex. The authors note the results may indicate a direct interaction between beta-amyloid and tangles, but secondary deposition or crossreactivity cannot be ruled out.

Study details

How this study scored 37/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 2 of 7; Citations per year 0 of 5; Impact for its field and year 2 of 6; Cited by studies here 1 of 6; Still being cited 0 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 37 of 100.37 of 100 points earned63 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of neuropathology and experimental neurology)
Journal's citation record 2 / 4 Journal of Neuropathology & Experimental Neurology: journal h-index 239 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1998 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (pubmed indexes it as a clinical or observational study)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 13 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.4 citations a year over 30 year(s) since 1998
Impact for its field and year 2 / 6 Cited 1.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Patrick L. McGeer: h-index 119 (OpenAlex, whole career)
Institution's track record 1 / 3 University of British Columbia: institution h-index 1,424 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 2 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 9862635)
Free to read 0 / 2 Behind a paywall — scores zero
Total 37 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Down syndrome and Alzheimer's

Also tagged “tdp-43”

1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.

Similar studies

More on Down syndrome and Alzheimer's

See all studies in Down syndrome and Alzheimer's →